Impact of handling BLQ PK data on PD estimation

Explicit modeling of BLQ data in WinBUGS® reduced bias in the PD predictions - a preclinical example Dartois C, Looby M, He H, Steimer J-L, and Pillai G Copenhagen, 14th June 2007



Agenda

- Objective
- Method
 - Data
 - Exploratory analysis
 - Modeling approach
- Results
 - PK modeling
 - Impact on PD modeling

Conclusion



Objective

- To compare 2 drugs, a lead compound and its backup on a pharmacodynamic endpoint based on their relative potency in animals
 - These 2 drugs are from the same therapeutic class
 - The pharmacodynamic endpoint studied is a biomarker activity
 - The effect of the drugs is to produce its inhibition



Study designs:



Method Exploratory analysis (PK)

Absorption variable (Cmax and Tmax) (1) Paucity of data in IC50 area for the lead (2)



5 | Handling missing data | Dartois C | 14th June 2007 | PAGE, Copenhagen.

STUDY 1 : Paucity of data in IC50 area for the lead (1)



Method Exploratory analysis (PD)

STUDY 2: a lot of noise specially in the recovery phase (1)



7 | Handling missing data | Dartois C | 14th June 2007 | PAGE, Copenhagen.



- Sequential PKPD with non linear mixed effect modeling
 - A lot of BLQ data in the PK (n=75/292 / n=2/292, Lead / Backup), paucity of data in IC50 area (Lead), a lot of noise in the PD (Lead / Backup), impossibility to use PD to better estimate PK.
 - Use individual PK prediction as an input for the PD.
- Diverse PK approach tested
 - Challenge for low concentrations and BLQ data
 - NONMEM V (IOV on F and Ka, log transformation of data), all BLQ data discarded
 - WinBUGS ® (LOQ taken into account identifying BLQ data, log transformation of data, each occasion = different animals)

PD modeling in NONMEM

 same Emax for the 2 drugs, different IC50s, different error models for the 2 studies **U**NOVARTIS

Results PK modeling

Goodness of fit, NONMEM

 For the lead, biased estimation of individual predictions in IC50 area **Backup** Lead



Goodness of fit in IC50 area, comparison with WinBUGS ®

6

NOVARTIS

- Biased estimation of individual predictions in IC50 area
- No real distinction between NONMEM and WinBUGS ®



NONMEM

10 | Handling missing data | Dartois C | 14th June 2007 | PAGE, Copenhagen.

Results PK modeling, for the LEAD

- Distribution of BLQ predictions, comparison with WinBUGS ® Estimation of BLQ data above LOQ for the 2 studies (in error)
 - Frequent in NONMEM, unusual for WinBUGS ®





^{12 |} Handling missing data | Dartois C | 14th June 2007 | PAGE, Copenhagen.



^{13 |} Handling missing data | Dartois C | 14th June 2007 | PAGE, Copenhagen.



If PK data predicted by WinBUGS ®, IC50 estimations different





If PK data predicted by WinBUGS ®, IC50 estimations identical



Results PK influence on PD estimation, relative potency



Results PK influence on PD estimation, relative potency

IC50 ratio estimated at 43, if PK data predicted by WinBUGS ®



- Handling BLQ data, already important for PK, can be crucial for PD estimation when IC50 around LOQ
- A large diversity of methodologies exists [1-2]
- Until now, due to implementation complexity and no big difference in efficiency, the simplest method (discarding all BLQ data) in NONMEM V was encouraging [1]
- In this study, we tested this method against Winbugs (for which LOQ is taken into account to explain BLQ data)

[1] Beal. JPP, 2001,28(5):481-504 [2] Beal. JPP, 2005, 32(2):213-243.



Conclusion - Perspectives

- The only graphic allowing to distinguish the methods was the BLQ distribution against the LOQ : Winbugs showed better results on PK, predicting only few concentrations above LOQ.
- This PK result had a great impact on PD estimation and reduce bias on relative potency (ratio of 43 instead of 24)
- As drugs are more and more potent and efficiency of analytical methods cannot always quantify with accuracy the concentrations of interest, a real need of handling BLQ data exists in PKPD modeling.
- New methods implemented in NONMEM VI represent an improvement. They need to be tested on this example.

NOVARTIS

Any questions?



MADE IN SWITZERLAND ®